Izeltabart tapatansine

他坦伊妥拜单抗

Report date: 2024/02/05 14:07:55

Base Information

Drug NameIzeltabart tapatansine

Drug Alias NameAnti-ADAM9 antibody-drug conjugate -ImmunoGenIMGC-936

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Tetrapeptide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM21 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionTubulin inhibitorsDisintegrin and metalloproteinase domain-containing protein 9 inhibitors

TargetsTubulinDisintegrin and metalloproteinase domain-containing protein 9

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesItalySpain

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesImmunogen Inc

China Registration ClassN/A

Develop Information

Active CompaniesImmunogen Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A